医学
前交叉韧带重建术
临床试验
前交叉韧带
骨整合
再生(生物学)
外科
重症监护医学
病理
植入
生物
细胞生物学
作者
Adam T. Hexter,Tanujan Thangarajah,Gordon Blunn,Fares S. Haddad
出处
期刊:The bone & joint journal
[British Editorial Society of Bone and Joint Surgery]
日期:2018-03-01
卷期号:100-B (3): 271-284
被引量:67
标识
DOI:10.1302/0301-620x.100b3.bjj-2017-0733.r2
摘要
Aims The success of anterior cruciate ligament reconstruction (ACLR) depends on osseointegration at the graft-tunnel interface and intra-articular ligamentization. Our aim was to conduct a systematic review of clinical and preclinical studies that evaluated biological augmentation of graft healing in ACLR. Materials and Methods In all, 1879 studies were identified across three databases. Following assessment against strict criteria, 112 studies were included (20 clinical studies; 92 animal studies). Results Seven categories of biological interventions were identified: growth factors, biomaterials, stem cells, gene therapy, autologous tissue, biophysical/environmental, and pharmaceuticals. The methodological quality of animal studies was moderate in 97%, but only 10% used clinically relevant outcome measures. The most interventions in clinical trials target the graft-tunnel interface and are applied intraoperatively. Platelet-rich plasma is the most studied intervention, but the clinical outcomes are mixed, and the methodological quality of studies was suboptimal. Other biological therapies investigated in clinical trials include: remnant-augmented ACLR; bone substitutes; calcium phosphate-hybridized grafts; extracorporeal shockwave therapy; and adult autologus non-cultivated stem cells. Conclusion There is extensive preclinical research supporting the use of biological therapies to augment ACLR. Further clinical studies that meet the minimum standards of reporting are required to determine whether emerging biological strategies will provide tangible benefits in patients undergoing ACLR. Cite this article: Bone Joint J 2018;100-B:271–84.
科研通智能强力驱动
Strongly Powered by AbleSci AI